Controversy: Critical Review of the Stich Trial and Assessment of Viability. “Back to the Future” Or Maybe Not
Published Online: Apr 22, 2022
Page range: 63 - 68
Received: Mar 10, 2022
Accepted: Mar 30, 2022
DOI: https://doi.org/10.2478/amb-2022-0011
Keywords
© 2022 V. Grigorov et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The management of patients with coronary artery disease and heart failure has been debated for years. In the 1980’s Braunwald coined the words “viability” and “stunning”. Multiple trials have been done since then. Since the early eighties coronary bypass grafting was considered as gold standard for patients with impaired left ventricular fraction and coronary artery disease. Since then, nuclear imaging studies have been used to evaluate the “viability” of the impaired areas and to decide if revascularisation would be reasonable. Beginning with the CASS study and ending with the more recent STICH study we aim to provide a “bird’s eye view” of the pros and cons for revascularisation. In addition, we aim to shed some light on the daily advancements in medical management, including devices and not just medication. We therefore chose the title “Back to the future” or maybe not.